Therefore, an accurate in vivo Tau assessment may improve our knowledge about the neuro-physiopathology of AD and dementia, and subsequently, may provide novel insight into the dementia field with a potential crucial impact on its management and treatment. The gene discussed is MAPT; the disease is dementia.